Every 10-Q that Precigen Inc (PGEN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PGEN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PGEN filings page.
Precigen, Inc. became profitable as Papzimeos commercial sales scaled. For the quarter ended June 30, 2026, it generated total revenues of $54,978 and net income of $20,071 versus revenues of $856 and a net loss of $26,642 a year earlier (amounts in thousands). For the first six months, revenues were $78,230 with net income of $12,142, compared with $2,197 and a net loss of $80,795 in 2025.
Papzimeos contributed $53,070 of Q2 product revenue and $74,661 year‑to‑date, with Exemplar providing additional product and service revenues. Despite earnings, operating activities used $61,636 of cash in the first half, mainly from higher trade receivables and inventory. As of June 30, 2026, cash, cash equivalents and investments totaled $38,698 against long‑term debt of $93,880 under a term loan maturing in 2030.
Papzimeos, approved by the FDA in August 2025 for adult recurrent respiratory papillomatosis, now benefits from seven-year orphan drug exclusivity through August 14, 2032, and a Marketing Authorization Application is under EMA review, while the company continues advancing its AdenoVerse and UltraCAR‑T pipeline programs.
Precigen, Inc. reported a sharp shift toward commercial operations in the quarter ended March 31, 2026, driven by sales of its first approved product, Papzimeos for recurrent respiratory papillomatosis. Total revenue rose to $23.3 million from $1.3 million a year earlier, including $21.6 million from Papzimeos and $1.7 million from Exemplar’s products and services.
Operating loss narrowed to $6.0 million from $22.6 million, and net loss improved to $7.9 million from $54.2 million, aided by the absence of prior-period warrant fair value charges. However, operating activities used $43.8 million of cash in the quarter, reflecting working capital buildup, inventory growth and higher selling, general and administrative expenses of $21.0 million to support the Papzimeos launch.
At March 31, 2026, Precigen held $56.7 million in cash, cash equivalents and investments and had $93.5 million in long‑term debt under a five‑year Pharmakon‑managed loan facility. The company emphasizes that continued commercialization of Papzimeos is key to its path toward profitability.
Precigen (PGEN) filed its Q3 2025 report highlighting a transition to commercialization after the FDA granted full approval in August for Papzimeos (zopapogene imadenovec) to treat recurrent respiratory papillomatosis. Q3 revenue was $2.9M, led by $1.8M of collaboration and licensing revenue recognized upon terminating a legacy PTC/Agilis agreement, with product and service revenue totaling $1.1M.
Operating expenses rose with launch preparation, including SG&A of $24.0M. The company reported a Q3 net loss of $146.3M, primarily driven by a non‑cash $111.5M loss from the change in fair value of warrant liabilities; a $179.0M deemed dividend on preferred stock increased the net loss attributable to common shareholders to $325.3M. Cash, cash equivalents and investments were $123.6M as of September 30, 2025, aided by a new $100.0M five‑year senior secured term loan to support the Papzimeos launch. Inventory of $3.1M was capitalized following approval. Common shares outstanding were 353,810,556 as of September 30, 2025.
Precigen, Inc. reported condensed financials for the quarter ended June 30, 2025 showing regulatory progress for its lead gene therapy and material financial strain. The FDA granted priority review to the Biologics License Application for PRGN-2012, with a PDUFA target action date of August 27, 2025; PRGN-2012 is intended to treat adults with recurrent respiratory papillomatosis and has not been approved.
Financially, the company recorded a net loss of $80,795 (amounts in thousands, i.e., $80.8 million) for the six months ended June 30, 2025 and used $35,302 of cash in operating activities in that period. As of June 30, 2025, it held $13,760 in cash and $45,993 in short-term investments (totaling $59,753). Warrant liabilities were $78,558 and Series A preferred mezzanine equity was $30,883, while accumulated deficit totaled $2,171,501. Management concluded these conditions raise substantial doubt about the company’s ability to continue as a going concern for one year absent additional funding or approval-related revenue.
Operationally, the company realigned to a single reporting segment and previously reduced its workforce by over 20% to focus resources on PRGN-2012. The company recorded a $3,907 goodwill impairment in Q2 2025 and recognized prior noncurrent asset impairments in 2024. These items, combined with large noncash warrant fair-value movements, contribute to earnings volatility despite regulatory momentum.